Identification and Characterization of BRCA1 and BRCA2 Founder Mutations

被引:1
|
作者
Sidoni, T. [1 ]
Cocciolone, V [1 ]
Giannini, G. [2 ]
Russo, A. [3 ]
Baudi, F. [4 ]
Cannita, K. [1 ]
Ficorella, C. [1 ]
Iacobelli, S. [5 ]
Ricevuto, E. [1 ]
机构
[1] Univ Aquila, Dept Expt Med, Med Oncol, Laquila, Italy
[2] Univ Roma La Sapienza, Dept Expt Med & Pathol, Serv Mol & Ultrastruct Pathol, Rome, Italy
[3] Univ Palermo, Reg Reference Ctr Biomol Characterizat & Genet Sc, Dept Surg & Oncol, Palermo, Italy
[4] Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin G Salvatore, Catanzaro, Italy
[5] Univ G dAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, Chieti, Italy
关键词
BRCA1; BRCA2; founder mutation;
D O I
10.2174/157340412799079192
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A large number of cancer predisposing BRCA1/BRCA2 mutations have been reported, with a wide variety among populations. In some restricted groups, specific germline mutations in these tumor suppressor genes have been found with high predominance, due to a founder effect. We focused our review on the Italian founder mutations. The first Italian BRCA1 founder mutation, 5083del19, was found in Calabria: the presence of common allele in all carriers of this mutation (also in families with Calabrian origin living in other parts of Italy) confirmed its founder effect. The same BRCA1 mutation was identified in the Sicilian population, but only the haplotype analysis can reveal the common ancestor of these groups. Another BRCA1 founder mutation, 4843delC, was found in Sicily. Four distinct BRCA1 mutations are attributable to families original from Tuscany: 3348delAG, 3285delA, 1499insA and 5183delTGT; the latter has been shown to be a founder mutation from North-Eastern Italy. The first BRCA2 mutation was identified in Sardinia, 8765delAG, a mutation already described as a founder mutation in Jewish-Yemenite families and also in French-Canadian population but with independent origins of carriers in these three populations. BRCA2 3951del3 and BRCA1 917delTT have been described as founder mutations in Middle Sardinia and in South and Middle Sardinia, respectively. Studies regarding prevalence and penetrance of founder mutations can allow to quantify the degree of homogeneity within a population and can surely help the geneticist and oncologist to simplify their choices in the genetic testing on high-risk families, on the basis of their ethnical origin.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 50 条
  • [41] The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer
    Kreiss, Y
    Barak, F
    Baruch, RG
    Levy-Lahad, E
    Pras, E
    Friedman, E
    [J]. GENETIC TESTING, 2000, 4 (04): : 403 - 407
  • [42] Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry
    Rosenthal, Eric
    Moyes, Kelsey
    Arnell, Christopher
    Evans, Brent
    Wenstrup, Richard J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 223 - 227
  • [43] Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry
    Eric Rosenthal
    Kelsey Moyes
    Christopher Arnell
    Brent Evans
    Richard J. Wenstrup
    [J]. Breast Cancer Research and Treatment, 2015, 149 : 223 - 227
  • [44] BRCA1 and BRCA2 mutations in a South American population
    Jara, L
    Ampuero, S
    Santibáñez, E
    Seccia, L
    Rodríguez, J
    Bustamante, M
    Martínez, V
    Catenaccio, A
    Lay-Son, G
    Blanco, R
    Reyes, JM
    [J]. CANCER GENETICS AND CYTOGENETICS, 2006, 166 (01) : 36 - 45
  • [45] Bone Loss in Women with BRCA1 and BRCA2 Mutations
    Salyer, Chelsea
    Alabaster, Amy
    Hamilton, Isabella
    Stoller, Nicole
    Raine-Bennett, Tina
    Powell, C. Bethan
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 212 - 213
  • [46] BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
    [J]. British Journal of Cancer, 2003, 88 : 1256 - 1262
  • [47] Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families
    Ewald, I. P.
    Vargas, F. R.
    Moreira, M. A.
    Filho, C. M.
    da Cunha, D. R.
    Ramos, J. P.
    Ribeiro, P. L.
    Caleffi, M.
    Giugliani, R.
    Ashton-Prolla, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] BRCA1 and BRCA2 families in Finland:: haplotype and phenotype analysis and predominance of founder mutations.
    Sarantaus, L
    Huusko, P
    Eerola, H
    Launonen, V
    Vehmanen, P
    Rapakko, K
    Gillanders, E
    Syrjäkoski, K
    Kainu, T
    Vahteristo, P
    Pääkkönen, K
    Hartikainen, J
    Blomqvist, C
    Löppönen, T
    Holli, K
    Mannermaa, A
    Kere, J
    Kallioniemi, OP
    Winqvist, R
    Nevanlinna, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A320 - A320
  • [49] Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in hungary
    Van der Looij, M
    Szabo, C
    Besznyak, I
    Liszka, G
    Csokay, B
    Pulay, T
    Toth, J
    Devilee, P
    King, MC
    Olah, E
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2000, 86 (05) : 737 - 740
  • [50] Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin
    Luna Kadouri
    Mark Temper
    Tal Grenader
    Dvorah Abeliovich
    Tamar Hamburger
    Tamar Peretz
    Michal Lotem
    [J]. Familial Cancer, 2009, 8 : 29 - 32